Branded Legacy, Inc. Acquires Bio Legacy Evaluative Group
Branded Legacy, Inc. (OTC: BLEG) has finalized its acquisition of Bio Legacy Evaluative Group (formerly Menlo Health), marking a...
TryVvio Nominated for Prestigious Prix Galien USA Award
Idorsia’s hypertension drug, Tryvio (aprocitentan), has been nominated for the prestigious Prix Galien USA award in the “Best Pharmaceutical...
Cosmos Health Invests $1M in ETH Under New Treasury Strategy
Cosmos Health, a global healthcare group, has initiated purchases of Ethereum (ETH), marking a notable shift in its treasury...
x4 Pharmaceuticals Gets $60M Equity Financing, Changes Management
X4 Pharmaceuticals secures $60 million in PIPE financing, marking a strategic inflection point for the rare disease company. This...
Rakovina & NanoPalm Announce Joint Venture for AI Oncology Therapies
Rakovina Therapeutics and Nanopalm are joining forces to develop novel oncology therapeutics, starting with KT-3283, a dual PARP-HDAC inhibitor,...
Imagene and Ikena Oncology Merger and $75M Private Placement Complete
Inmagene Biopharmaceuticals and Ikena Oncology have finalized their merger, creating Imagenebio, a clinical-stage biotech focused on immunology and inflammatory...
Qubee Hive Holdings Launched to Advance Web3 Financial Infrastructure
Full Alliance Group, Inc. (FAGI) is establishing a new subsidiary, QUBEE HIVE HOLDINGS, INC., under its Qubitera Holdings arm,...
Agios’ Pyrukynd® (Mitapivat) Approved for Thalassemia in Saudi Arabia
Agios Pharmaceuticals has secured its first regulatory win for Pyrukynd (mitapivat) in thalassemia, with the Saudi Food and Drug...
Bobot Debuts as Public Company: Targeting RAS Pathway Malignancies
BridgeBio Oncology Therapeutics (BBOT) has officially launched on the Nasdaq Global Market under the ticker symbol “BBOT,” following a...
Tevogen Projects $1B Launch Revenue, $10-14B Over 5 Years
Tevogen Bio projects ambitious revenue figures for its oncology pipeline, forecasting $1 billion in its launch year and a...